Advertisement

Hypophosphatasia in Japan: ALPL Mutation Analysis in 98 Unrelated Patients

  • Toshimi MichigamiEmail author
  • Kanako Tachikawa
  • Miwa Yamazaki
  • Masanobu Kawai
  • Takuo Kubota
  • Keiichi Ozono
Original Research

Abstract

Hypophosphatasia (HPP) is highly variable in clinical expression and is generally classified into six subtypes. Although it would be beneficial to be able to predict the clinical course from the ALPL genotype, studies on this issue are limited. Here, we aimed to clarify the features of Japanese HPP and the relationships between genotype and clinical manifestations. We analyzed 98 unrelated Japanese patients to investigate the percentage of each clinical form, frequently detected mutations, and the relationship between the genotype and phenotype. Some of the identified mutants were characterized by transfection experiments. Perinatal severe form was the most frequent (45.9%), followed by perinatal benign form (22.4%). Among the 196 alleles, p.Leu520ArgfsX86 (c.1559delT) was detected in 89 alleles, and p.Phe327Leu (c.979T>C) was identified in 23 alleles. All of the homozygotes for p.Leu520ArgfsX86 were classified into perinatal severe form, and patients carrying p.Phe327Leu in one of the alleles were classified into perinatal benign or odonto HPP. Twenty of the 22 patients with perinatal benign HPP were compound heterozygous for p.Phe327Leu and another mutation. Most patients with odonto HPP were found to be monoallelic heterozygotes for dominant-negative mutations or compound heterozygotes with mutants having residual activity. The high prevalence of p.Leu520ArgfsX86 and p.Phe327Leu mutations might underlie the high rate of perinatal severe and perinatal benign forms, respectively, in Japanese HPP. Although ALPL genotyping would be beneficial for predicting the clinical course to an extent, the observed phenotypical variability among patients sharing the same genotypes suggests the presence of modifiers.

Keywords

Hypophosphatasia Mutations Genotype–phenotype correlation ALPL 

Notes

Acknowledgements

The authors thank all the patients, families, and doctors who contributed to this study. This work was supported by a grant from the Japan Agency for Medical Research and Development (AMED) Practical Research Project for Rare/Intractable Disease Project of Japan (17ek010935h0003), and by Research on rare and intractable diseases, Health, Labour and Welfare Sciences Research Grants (19FC1006).

Compliance with Ethical Standards

Conflict of interest

Toshimi Michigami, Kanako Tachikawa, Miwa Yamazaki, Masanobu Kawai, Takuo Kubota, and Keiichi Ozono declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

Informed consent was obtained from the patients or guardians of minor patients.

References

  1. 1.
    Whyte MP (2016) Hypophosphatasia—aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 12:233–246CrossRefGoogle Scholar
  2. 2.
    Mornet E (2007) Hypophosphatasia. Orphanet J Rare Dis 2:40CrossRefGoogle Scholar
  3. 3.
    Mornet E, Nunes ME (2007) Hypophosphatasia. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (eds) GeneReviews®. University of Washington, SeattleGoogle Scholar
  4. 4.
    Wenkert D, McAlister WH, Coburn SP, Zerega JA, Ryan LM, Ericson KL, Hersh JH, Mumm S, Whyte MP (2011) Hypophosphatasia: nonlethal disease despite skeletal presentation in utero (17 new cases and literature review). J Bone Miner Res 26:2389–2398CrossRefGoogle Scholar
  5. 5.
    Ozono K, Yamagata M, Michigami T, Nakajima S, Sakai N, Cai G, Satomura K, Yasui N, Okada S, Nakayama M (1996) Identification of novel missense mutations (Phe310Leu and Gly439Arg) in a neonatal case of hypophosphatasia. J Clin Endocrinol Metab 81:4458–4461PubMedGoogle Scholar
  6. 6.
    Simon-Bouy B, Taillandier A, Fauvert D, Brun-Heath I, Serre JL, Armengod CG, Bialer MG, Mathieu M, Cousin J, Chitayat D, Liebelt J, Feldman B, Gerard-Blanluet M, Kortge-Jung S, King C, Laivuori H, Le Merrer M, Mehta S, Jern C, Sharif S, Prieur F, Gillessen-Kaesbach G, Zankl A, Mornet E (2008) Hypophosphatasia: molecular testing of 19 prenatal cases and discussion about genetic counseling. Prenat Diagn 28:993–998CrossRefGoogle Scholar
  7. 7.
    Yadav MC, de Oliveira RC, Foster BL, Fong H, Cory E, Narisawa S, Sah RL, Somerman M, Whyte MP, Millan JL (2012) Enzyme replacement prevents enamel defects in hypophosphatasia mice. J Bone Miner Res 27:1722–1734CrossRefGoogle Scholar
  8. 8.
    Whyte MP, Rockman-Greenberg C, Ozono K, Riese R, Moseley S, Melian A, Thompson DD, Bishop N, Hofmann C (2016) Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol Metab 101:334–342CrossRefGoogle Scholar
  9. 9.
    Okazaki Y, Kitajima H, Mochizuki N, Kitaoka T, Michigami T, Ozono K (2016) Lethal hypophosphatasia successfully treated with enzyme replacement from day 1 after birth. Eur J Pediatr 175:433–437CrossRefGoogle Scholar
  10. 10.
    Kitaoka T, Tajima T, Nagasaki K, Kikuchi T, Yamamoto K, Michigami T, Okada S, Fujiwara I, Kokaji M, Mochizuki H, Ogata T, Tatebayashi K, Watanabe A, Yatsuga S, Kubota T, Ozono K (2017) Safety and efficacy of treatment with asfotase alfa in patients with hypophosphatasia: results from a Japanese clinical trial. Clin Endocrinol (Oxf) 87:10–19CrossRefGoogle Scholar
  11. 11.
    Zurutuza L, Muller F, Gibrat JF, Taillandier A, Simon-Bouy B, Serre JL, Mornet E (1999) Correlations of genotype and phenotype in hypophosphatasia. Hum Mol Genet 8:1039–1046CrossRefGoogle Scholar
  12. 12.
    Mornet E (2015) Molecular genetics of hypophosphatasia and phenotype–genotype correlations. Subcell Biochem 76:25–43CrossRefGoogle Scholar
  13. 13.
    Michigami T, Uchihashi T, Suzuki A, Tachikawa K, Nakajima S, Ozono K (2005) Common mutations F310L and T1559del in the tissue-nonspecific alkaline phosphatase gene are related to distinct phenotypes in Japanese patients with hypophosphatasia. Eur J Pediatr 164:277–282CrossRefGoogle Scholar
  14. 14.
    Matsushita M, Kitoh H, Michigami T, Tachikawa K, Ishiguro N (2014) Benign prenatal hypophosphatasia: a treatable disease not to be missed. Pediatr Radiol 44:340–343CrossRefGoogle Scholar
  15. 15.
    Ikenoue S, Miyakoshi K, Ishii T, Sato Y, Otani T, Akiba Y, Kasuga Y, Ochiai D, Matsumoto T, Ichihashi Y, Matsuzaki Y, Tachikawa K, Michigami T, Nishimura G, Ikeda K, Hasegawa T, Tanaka M (2018) Discordant fetal phenotype of hypophosphatasia in two siblings. Am J Med Genet A 176:171–174CrossRefGoogle Scholar
  16. 16.
    Oyachi M, Harada D, Sakamoto N, Ueyama K, Kondo K, Kishimoto K, Izui M, Nagamatsu Y, Kashiwagi H, Yamamuro M, Tamura M, Kikuchi S, Akiyama T, Michigami T, Seino Y, Namba N (2018) A case of perinatal hypophosphatasia with a novel mutation in the ALPL gene: clinical course and review of the literature. Clin Pediatr Endocrinol 27:179–186CrossRefGoogle Scholar
  17. 17.
    Ishiguro T, Sugiyama Y, Ueda K, Muramatsu Y, Tsuda H, Kotani T, Michigami T, Tachikawa K, Akiyama T, Hayakawa M (2019) Findings of amplitude-integrated electroencephalogram recordings and serum vitamin B6 metabolites in perinatal lethal hypophosphatasia during enzyme replacement therapy. Brain Dev 41(8):721–725CrossRefGoogle Scholar
  18. 18.
    Akiyama T, Kubota T, Ozono K, Michigami T, Kobayashi D, Takeyari S, Sugiyama Y, Noda M, Harada D, Namba N, Suzuki A, Utoyama M, Kitanaka S, Uematsu M, Mitani Y, Matsunami K, Takishima S, Ogawa E, Kobayashi K (2018) Pyridoxal 5'-phosphate and related metabolites in hypophosphatasia: effects of enzyme replacement therapy. Mol Genet Metab 125:174–180CrossRefGoogle Scholar
  19. 19.
    Henthorn PS, Whyte MP (1992) Missense mutations of the tissue-nonspecific alkaline phosphatase gene in hypophosphatasia. Clin Chem 38:2501–2505PubMedGoogle Scholar
  20. 20.
    Cai G, Michigami T, Yamamoto T, Yasui N, Satomura K, Yamagata M, Shima M, Nakajima S, Mushiake S, Okada S, Ozono K (1998) Analysis of localization of mutated tissue-nonspecific alkaline phosphatase proteins associated with neonatal hypophosphatasia using green fluorescent protein chimeras. J Clin Endocrinol Metab 83:3936–3942PubMedGoogle Scholar
  21. 21.
    Fauvert D, Brun-Heath I, Lia-Baldini AS, Bellazi L, Taillandier A, Serre JL, de Mazancourt P, Mornet E (2009) Mild forms of hypophosphatasia mostly result from dominant negative effect of severe alleles or from compound heterozygosity for severe and moderate alleles. BMC Med Genet 10:51CrossRefGoogle Scholar
  22. 22.
    Lia-Baldini AS, Muller F, Taillandier A, Gibrat JF, Mouchard M, Robin B, Simon-Bouy B, Serre JL, Aylsworth AS, Bieth E, Delanote S, Freisinger P, Hu JC, Krohn HP, Nunes ME, Mornet E (2001) A molecular approach to dominance in hypophosphatasia. Hum Genet 109:99–108CrossRefGoogle Scholar
  23. 23.
    Komaru K, Satou Y, Al-Shawafi HA, Numa-Kinjoh N, Sohda M, Oda K (2016) Glycosylation-deficient mutations in tissue-nonspecific alkaline phosphatase impair its structure and function and are linked to infantile hypophosphatasia. FEBS J 283:1168–1179CrossRefGoogle Scholar
  24. 24.
    Mornet E, Taillandier A, Peyramaure S, Kaper F, Muller F, Brenner R, Bussiere P, Freisinger P, Godard J, Le Merrer M, Oury JF, Plauchu H, Puddu R, Rival JM, Superti-Furga A, Touraine RL, Serre JL, Simon-Bouy B (1998) Identification of fifteen novel mutations in the tissue-nonspecific alkaline phosphatase (TNSALP) gene in European patients with severe hypophosphatasia. Eur J Hum Genet 6:308–314CrossRefGoogle Scholar
  25. 25.
    Taillandier A, Zurutuza L, Muller F, Simon-Bouy B, Serre JL, Bird L, Brenner R, Boute O, Cousin J, Gaillard D, Heidemann PH, Steinmann B, Wallot M, Mornet E (1172delC) Characterization of eleven novel mutations (M45L, R119H, 544delG, G145V, H154Y, C184Y, D289V, 862+5A, 1172delC, R411X, E459K) in the tissue-nonspecific alkaline phosphatase (TNSALP) gene in patients with severe hypophosphatasia. Mutations in brief no. 217. Hum Mutat 13:171–172CrossRefGoogle Scholar
  26. 26.
    Saglam H, Erdol S, Dorum S (2017) Clinical and genetic findings of Turkish hypophosphatasia cases. J Clin Res Pediatr Endocrinol 9:229–236CrossRefGoogle Scholar
  27. 27.
    Muller HL, Yamazaki M, Michigami T, Kageyama T, Schonau E, Schneider P, Ozono K (2000) Asp361Val mutant of alkaline phosphatase found in patients with dominantly inherited hypophosphatasia inhibits the activity of the wild-type enzyme. J Clin Endocrinol Metab 85:743–747CrossRefGoogle Scholar
  28. 28.
    Whyte MP (2017) Hypophosphatasia: enzyme replacement therapy brings new opportunities and new challenges. J Bone Miner Res 32:667–675CrossRefGoogle Scholar
  29. 29.
    Weiss MJ, Henthorn PS, Lafferty MA, Slaughter C, Raducha M, Harris H (1986) Isolation and characterization of a cDNA encoding a human liver/bone/kidney-type alkaline phosphatase. Proc Natl Acad Sci USA 83:7182–7186CrossRefGoogle Scholar
  30. 30.
    Goseki-Sone M, Orimo H, Iimura T, Miyazaki H, Oda K, Shibata H, Yanagishita M, Takagi Y, Watanabe H, Shimada T, Oida S (1998) Expression of the mutant (1735T-DEL) tissue-nonspecific alkaline phosphatase gene from hypophosphatasia patients. J Bone Miner Res 13:1827–1834CrossRefGoogle Scholar
  31. 31.
    Watanabe A, Karasugi T, Sawai H, Naing BT, Ikegawa S, Orimo H, Shimada T (2011) Prevalence of c.1559delT in ALPL, a common mutation resulting in the perinatal (lethal) form of hypophosphatasia in Japanese and effects of the mutation on heterozygous carriers. J Hum Genet 56:166–168CrossRefGoogle Scholar
  32. 32.
    Mornet E, Yvard A, Taillandier A, Fauvert D, Simon-Bouy B (2011) A molecular-based estimation of the prevalence of hypophosphatasia in the European population. Ann Hum Genet 75:439–445CrossRefGoogle Scholar
  33. 33.
    Greenberg CR, Taylor CL, Haworth JC, Seargeant LE, Philipps S, Triggs-Raine B, Chodirker BN (1993) A homoallelic Gly317–%3eAsp mutation in ALPL causes the perinatal (lethal) form of hypophosphatasia in Canadian mennonites. Genomics 17:215–217CrossRefGoogle Scholar
  34. 34.
    Whyte MP, Essmyer K, Geimer M, Mumm S (1348c) Homozygosity for TNSALP mutation 1348c%3eT (Arg433Cys) causes infantile hypophosphatasia manifesting transient disease correction and variably lethal outcome in a kindred of black ancestry. J Pediatr 148:753–758CrossRefGoogle Scholar
  35. 35.
    Hofmann C, Girschick H, Mornet E, Schneider D, Jakob F, Mentrup B (2014) Unexpected high intrafamilial phenotypic variability observed in hypophosphatasia. Eur J Hum Genet 22:1160–1164CrossRefGoogle Scholar
  36. 36.
    Taillandier A, Domingues C, Dufour A, Debiais F, Guggenbuhl P, Roux C, Cormier C, Cortet B, Porquet-Bordes V, Coury F, Genevieve D, Chiesa J, Colin T, Fletcher E, Guichet A, Javier RM, Laroche M, Laurent M, Lausch E, LeHeup B, Lukas C, Schwabe G, van der Burgt I, Muti C, Simon-Bouy B, Mornet E (2018) Genetic analysis of adults heterozygous for ALPL mutations. J Bone Miner Metab 36:723–733CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Toshimi Michigami
    • 1
    Email author
  • Kanako Tachikawa
    • 1
  • Miwa Yamazaki
    • 1
  • Masanobu Kawai
    • 1
  • Takuo Kubota
    • 2
  • Keiichi Ozono
    • 2
  1. 1.Department of Bone and Mineral Research, Research Institute, Osaka Women’s and Children’s HospitalOsaka Prefectural Hospital OrganizationIzumiJapan
  2. 2.Department of PediatricsOsaka University Graduate School of MedicineSuitaJapan

Personalised recommendations